Levothyroxine sodium 0.125 MG Oral Tablet [Levoxyl] — RxCUI 966190
RxNorm drug concept · Semantic branded drug
RxCUI 966190
Semantic branded drug · SBD
● Current RxNorm concept 11 FDA products
22 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI966190
Official nameLevothyroxine sodium 0.125 MG Oral Tablet [Levoxyl]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asLevoxyl 125 MCG Oral Tablet; Levoxyl 0.125 MG Oral Tablet
FDA products mapped11
Package NDCs mapped22
Reported Medicaid activity (SDUD)18,566 prescriptions · 32 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Levothyroxine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It replaces thyroid hormone when your thyroid doesn’t make enough, a condition called hypothyroidism. Oral forms are also used with surgery and radioiodine for certain thyroid canc...
- Oral forms are usually taken once a day on an empty stomach, about 15 to 60 minutes before breakfast, depending on the product. Keep calcium, iron and antacids at least 4 hours awa...
- Full effect may take 4 to 6 weeks. Your doctor will check TSH and/or T4 blood tests to adjust your dose.
- No. It doesn’t cause weight loss at normal doses if your thyroid is normal. Larger doses can be seriously toxic.
🕸️ Concept Web — How Levothyroxine sodium 0.125 MG Oral Tablet [Levox... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Levothyroxine sodium 0.125 MG Oral Tablet [Levoxyl]
RxCUI 966190 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Levothyroxine
10582IN -
Levothyroxine sodium
40144PIN
-
Levothyroxine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Levoxyl
218002BN
-
Levoxyl
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Levothyroxine Oral Tablet
372595SCDF -
Levothyroxine sodium Oral Tablet
2649207SCDFP -
Levothyroxine Oral Product
1602753SCDG -
Levothyroxine Pill
1602745SCDG -
Levothyroxine sodium Oral Product
2662680SCDGP -
Levothyroxine sodium Pill
2661467SCDGP -
Levothyroxine Oral Tablet [Levoxyl]
705971SBDF -
Levothyroxine sodium Oral Tablet [Levoxyl]
2657937SBDFP - +5 more in this family
-
Levothyroxine Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Levothyroxine sodium 0.125 MG Oral Tablet
966224SCD -
Levothyroxine sodium 0.125 MG
966260SCDC -
Levothyroxine sodium 0.125 MG [Levoxyl]
966341SBDC
-
Levothyroxine sodium 0.125 MG Oral Tablet
Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Levothyroxine sodium 0.125 MG Oral Tablet
SCD · 966224 -
Levothyroxine sodium 0.125 MG
SCDC · 966260 -
Levothyroxine Oral Tablet
SCDF · 372595 -
Levothyroxine sodium Oral Tablet
SCDFP · 2649207 -
Levothyroxine Oral Product
SCDG · 1602753 -
Levothyroxine Pill
SCDG · 1602745 -
Levothyroxine sodium Oral Product
SCDGP · 2662680 -
Levothyroxine sodium Pill
SCDGP · 2661467
Brand-Name Concepts
-
Levothyroxine sodium 0.125 MG [Levoxyl]
SBDC · 966341 -
Levothyroxine Oral Tablet [Levoxyl]
SBDF · 705971 -
Levothyroxine sodium Oral Tablet [Levoxyl]
SBDFP · 2657937 -
Levoxyl Oral Product
SBDG · 1185573 -
Levoxyl Pill
SBDG · 1185574 -
Levoxyl
BN · 218002
📦 FDA Products & Package NDCs
11 products · 22 package NDCs
22 package NDCs map to RxCUI 966190 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 60793-0850-01 | 100 TABLET in 1 BOTTLE (60793-850-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0850-10 | 1000 TABLET in 1 BOTTLE (60793-850-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0851-01 | 100 TABLET in 1 BOTTLE (60793-851-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0851-10 | 1000 TABLET in 1 BOTTLE (60793-851-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0852-01 | 100 TABLET in 1 BOTTLE (60793-852-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0852-10 | 1000 TABLET in 1 BOTTLE (60793-852-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0853-01 | 100 TABLET in 1 BOTTLE (60793-853-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0853-10 | 1000 TABLET in 1 BOTTLE (60793-853-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0854-01 | 100 TABLET in 1 BOTTLE (60793-854-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0854-10 | 1000 TABLET in 1 BOTTLE (60793-854-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0855-01 | 100 TABLET in 1 BOTTLE (60793-855-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0855-10 | 1000 TABLET in 1 BOTTLE (60793-855-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0856-01 | 100 TABLET in 1 BOTTLE (60793-856-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0856-10 | 1000 TABLET in 1 BOTTLE (60793-856-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0857-01 | 100 TABLET in 1 BOTTLE (60793-857-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0857-10 | 1000 TABLET in 1 BOTTLE (60793-857-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0858-01 | 100 TABLET in 1 BOTTLE (60793-858-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0858-10 | 1000 TABLET in 1 BOTTLE (60793-858-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0859-01 | 100 TABLET in 1 BOTTLE (60793-859-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0859-10 | 1000 TABLET in 1 BOTTLE (60793-859-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0860-01 | 100 TABLET in 1 BOTTLE (60793-860-01) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
| 60793-0860-10 | 1000 TABLET in 1 BOTTLE (60793-860-10) | LEVOXYL | Pfizer Laboratories Div Pfizer Inc | 2001-05-25 |
Observed labelers:
Pfizer Laboratories Div Pfizer Inc (22)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.